Publications by authors named "Tamika Lords"

1 Publications

  • Page 1 of 1

In vivo longitudinal imaging of RNA interference-induced endocrine therapy resistance in breast cancer.

J Biophotonics 2020 01 9;13(1):e201900180. Epub 2019 Oct 9.

Division of Molecular Imaging, Department of Radiology, Baylor College of Medicine, Houston, Texas.

Endocrine therapy resistance in breast cancer is a major obstacle in the treatment of patients with estrogen receptor-positive (ER+) tumors. Herein, we demonstrate the feasibility of longitudinal, noninvasive and semiquantitative in vivo molecular imaging of resistance to three endocrine therapies by using an inducible fluorescence-labeled short hairpin RNA (shRNA) system in orthotopic mice xenograft tumors. We employed a dual fluorescent doxycycline (Dox)-regulated lentiviral inducer system to transfect ER+ MCF7L breast cancer cells, with green fluorescent protein (GFP) expression as a marker of transfection and red fluorescent protein (RFP) expression as a surrogate marker of Dox-induced tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN) knockdown. Xenografted MCF7L tumor-bearing nude mice were randomized to therapies comprising estrogen deprivation, tamoxifen or an ER degrader (fulvestrant) and an estrogen-treated control group. Longitudinal imaging was performed by a home-built multispectral imaging system based on a cooled image intensified charge coupled device camera. The GFP signal, which corresponds to number of viable tumor cells, exhibited excellent correlation to caliper-measured tumor size (Pā€‰<ā€‰.05). RFP expression was substantially higher in mice exhibiting therapy resistance and strongly and significantly (Pā€‰<ā€‰1e-7) correlated with the tumor size progression for the mice with shRNA-induced PTEN knockdown. PTEN loss was strongly correlated with resistance to estrogen deprivation, tamoxifen and fulvestrant therapies.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
January 2020